Bleeding and thrombosis in acute leukemia: What does the future of therapy look like?

Thrombosis Research

Volumn 120, Issue SUPPL. 2, 2007, Pages

  Rickles, Frederick R ^a   Falanga, Anna ^b   Montesinos, Pau ^c   Sanz, Miguel A ^c   Brenner, Benjamin ^d   Barbui, Tiziano ^b  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b OSPEDALI RIUNITI   (Italy)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Anticoagulant therapy; Bleeding; Leukemia; Venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; AMINOCAPROIC ACID; APROTININ; ARGATROBAN; BLOOD CLOTTING FACTOR 7A INHIBITOR; FONDAPARINUX; HEPARIN; HIRUDIN; HIRULOG; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; PROTEINASE INHIBITOR; RETINOIC ACID; TRANEXAMIC ACID; WARFARIN;

ACUTE LEUKEMIA; ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; CANCER CHEMOTHERAPY; CLINICAL FEATURE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RISK ASSESSMENT; THROMBOCYTOPENIA; THROMBOSIS; THROMBOSIS PREVENTION; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ACUTE DISEASE; ANTICOAGULANTS; ANTINEOPLASTIC AGENTS; HEMORRHAGE; HUMANS; LEUKEMIA; THROMBOSIS;

EID: 36148968812     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(07)70137-8     Document Type: Article

References (40)

1. Barbui T., Finazzi G., and Falanga A. The management of bleeding and thrombosis in acute leukemia and chronic myeloproliferative disorders. In: Henderson E., Lister T., and Greaves M. (Eds). Leukemia. 7th ed. (2001), WB Saunders Company 363-382
2. Falanga A., and Rickles F. Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia. Best Pract Res Clin Haematol 16 (2003) 463-482
3. Blom J., Doggen C., Osanto S., and Rosendaal F. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. J Am Med Assoc 293 (2005) 715-722
4. White R., Chew H., Zhou H., Parikh-Patel A., Harris D., Harvey D., and Wun T. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med 165 (2005) 1782-1787
5. Khorana A., Francis C., Culakova E., Fisher R., Kuderer N., and Lyman G. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 24 (2006) 484-490
6. Khorana A., Francis C., Culakova E., Kuderer N., and Lyman G. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5 (2007) 632-634
7. Karthaus M., Kretzschmar A., Kroning H., Biakhov M., Irwin D., Marschner N., et al. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol 17 (2006) 289-296
8. Verso M., Agnelli G., Bertoglio S., Di Somma F., Paoletti F., Ageno W., et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol 23 (2005) 4057-4062
9. Cortelezzi A., Moia M., Falanga A., Pogliani E., Agnelli G., Bonizzoni E., et al., CATHEM study group. Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study. Br J Hematol 129 (2005) 811-817
10. Couban S., Goodyear M., Burnell M., Dolan S., Wasi P., Barnes D., et al. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol 23 (2005) 4063-4069
11. Lee A., Levine M., Butler G., Webb C., Costantini L., Gu C., et al. Incidence, risk factors and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol 24 (2006) 1404-1408
12. Journeycake J., and Buchanan G. Catheter-related deep venous thrombosis and other catheter complications in children with cancer. J Clin Oncol 24 (2006) 4575-4580
13. Kovacs M., Kahn S., Rodger M., Anderson D., Andreou R., Mangel J., et al. A pilot study of central venous cathetr survival in cancer patients using low-molecular-weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The Catheter Study). J Thromb Haemost 5 (2007) 1650-1653
14. Dvorak H., and Rickles F. Malignancy and hemostasis. In: Colman R., Marder V., Clowes A., George J., and Goldhaber S. (Eds). Hemostasis and thrombosis, basic principles and clinical practice (2006), LippincottWilliams & Wilkins, Philadelphia, PA 851-873
15. Rickles F., and Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res 102 (2001) V215-V224
16. Ziegler S., Sperr W., Knobl P., Lehr S., Weltermann A., Jager U., et al. Symptomatic venous thromboembolism in acute leukemia. Incidence, risk factors, and impact on prognosis. Thromb Res 115 (2005) 59-64
17. De Stefano V., Sora F., Rossi E., Chiusolo P., Laurenti L., Fianchi L., et al. The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment. J Thromb Haemost 3 (2005) 1985-1992
18. Montesinos P., De la Serna J., Vellenga E., Rayon C., Bergua J., Parody R., et al. Incidence and risk factors for thrombosis in patients with acute promyelocytic leukemia. Experience of the PETHEMA LPA96 and LPA99 protocols. Blood 108 (2006) 1503 Abstract.
19. Boccaccio C., Sabatino G., Medico E., Girolami F., Follenzi A., Reato G., et al. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature 434 (2005) 396-400
20. Rong Y., Post D., Pieper R., Burden D., Van Meir E., and Brat D. PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res 65 (2005) 1406-1413
21. Yu J., May L., Lhotak V., Shahrzad S., Shirasawa S., Weitz J., et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 105 (2005) 1734-1741
22. Rickles F. Mechanisms of cancer-induced thrombosis. J Pathophysiol Haemost Thromb 35 (2006) 103-111
23. B̈uller H., Agnelli G., Hull R., Hyers R., Prins M., and Raskob G. Antithrombotic therapy for venous thromboembolic disease. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126 Suppl (2004) 401S-428S
24. National Comprehensive Cancer Network, Inc. NCCN Practice Guidelines in Oncology V2.2006, October 11, 2006.
25. Mandala M., Falanga A., Piccioli A., Prandoni P., Pogliani E., Labianca R., et al., on behalf of the working group AIOM. Venous thromboembolism and cancer: Guidelines of the Italian Society of Oncology (AIOM). Crit Rev Oncol/Hematol 59 (2006) 194-204
26. Lyman G., Khorana A., Falanga A., Clarke-Pearson D., Flowers C., Jahnanzeb M., et al. American Society of Clinical Oncology Guidelines: recommendations for venous thromboembolism prophylaxis in patients with cancer. In Preparation (2007)
27. Lee A., Levine M., Baker R., Bowden C., Kakkar A., Prins M., et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349 (2003) 146-153
28. Falanga A., Marchetti M., Vignoli A., Balducci D., Russo L., Guerini V., et al. V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte and plasma hemostatic and inflammatory molecules. Exp Hematol 35 (2007) 702-711 erratum: 1476.
29. Tallman M., Lefebvre P., Baine R., Shoji M., Cohen I., Green D., et al. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia. J Thromb Haemost 2 (2004) 1341-1350
30. Menell J., Cesarman G., Jacovina A., McLaughlin M., Lev E., and Hajjar K. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 340 (1999) 994-1004
31. Cozzolino F., Torcia M., Miliani A., Carossino A., Giordani R., Cinotti S., et al. Potential role of interleukin-1 as the trigger for diffuse intravascular coagulation in acute nonlymphoblastic leukemia. Am J Med 84 (1988) 240-250
32. de la Serna J, Montesinos P, Vellenga E, Rayon C, Parody R, Leon A, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. 2007, Submitted for Publication.
33. Montesinos P., and Sanz M. Incidence and prognostic factors for hemorrhagic death in patients with acute myeloid leukemia: a single-centre historical report. Thromb Res (2007) in press.
34. Herishanu Y., Misgav M., Kirgner I., Ben-Tal O., Eldor A., and Naparstek E. Enoxaparin can be used safely in patients with severe thrombocytopenia due to intensive chemotherapy regimens. Leukemia & Lymphoma 45 (2004) 1407-1411
35. Imberti D., Vallisa D., Anselmi E., Moroni C., Bertè R., Lazzaro A., et al. Safety and efficacy of enoxaparin treatment in venous thromboembolic disease during acute leukemia. Tumori 90 (2004) 1-4
36. The PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism. The PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation 112 (2005) 416-422
37. Rodeghiero F., Avvisati G., Castaman G., Barbui T., and Mandelli F. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood 75 (1990) 2112-2117
38. Falanga A., Marchetti M., Vignoli A., Balducci D., and Barbui T. Leukocyte platelet interactions in patients with essential thrombocythemia and polycythemia vera. Exp Haematol 33 (2005) 523-530
39. Hashimoto S., Koike T., Tatewaki W., Seki Y., Sato N., Azegami T., et al. Fatal thromboembolism in acute promyelocytic leukemia during all-trans-retinoic acid therapy combined with antifibrinolytic therapy for prophylaxis of hemorrhage. Leukemia 8 (1994) 1113-1115
40. Sanz M., Martin G., Gonzalez M., Leon A., Rayon C., Rivas C., et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 103 (2004) 1237-1243